Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Crizotinib
État du projet:
Terminé
Domaine thérapeutique:
Advanced or Metastatic Non-Small Cell Lung Cancer
Fabricant:
Pfizer Canada Inc.
Brand Name:
Xalkori
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0017-000
Strength:
200mg and 250mg
Tumour Type:
Lung
Indications:
Advanced Non-Small Cell Lung Cancer
Funding Request:
As monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Review Status:
Complete
Date NOC Issued:
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
Clarification:
As per pCODR Procedures D3.2, due to the short time frame between the original submission and the resubmission, pCODR will not be seeking new patient advocacy group input. The most recent patient advocacy group input received on the original submission related to Crizotinib (Xalkori) for Advanced NSCLC will be provided to the Review Team to incorporate into the Clinical and Economic Guidance Reports and to pERC for the purposes of their deliberation.
pERC Meeting:
Final Recommendation Issued:
The manufacturer, Pfizer Canada Inc. has resubmitted to pCODR for the Crizotinib (Xalkori) Advanced NSCLC submission. Please see the Crizotinib (Xalkori) for Advanced NSCLC Details page for information pertaining to the original submission.
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016